Navigation Links
Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
Date:11/13/2011

rimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently being studied in an interferon-free, Phase 3 program (FISSION and POSITRON) and in five Phase 2b trials in subjects with all HCV genotypes. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, is in QUANTUM, a Phase 2b interferon-free trial of PSI-7977 and PSI-938 in subjects with all HCV genotypes. Mericitabine (RG7128) continues in three Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice +1 (609) 865-0693 Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset to Webcast an Investor Event from the AASLD Meeting
2. Pharmasset to Present at Four Upcoming Investor Conferences
3. Pharmasset to Present at Canaccord Adams Conference
4. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
6. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
7. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
8. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
9. Pharmasset to Present at Two Upcoming Investor Conferences
10. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
11. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
(Date:7/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on Potassium ... basic information, including its definition, classification, application, ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis, the ...
(Date:7/24/2014)... 24, 2014 The first part of ... in First in Human Studies” will cover comprehensive clinical ... decisions. , With increasing R&D costs and declining industry ... to maximize the knowledge collected in early Phase I/IIa ... success in late stage development. , Next, the presenters ...
(Date:7/24/2014)... As part of the long-term strategic approach, ... region during 2014 with potential global expansion. , "We ... DZS to manage our clinical trials globally and in ... R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh ... a focus on utilizing eClinical software and flexible team ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Mano Receive 2008 JCA-Mauvernay Award, LAUSANNE, ... global biopharmaceutical development specialist that,focuses on serious ... Ichijo and Hiroyuki Mano with the 2008 ... research work in oncology.,The Awards were presented ...
... Preclinical Animal Data Demonstrates Selective Survival Advantage of ... Reduced Viral Loads, WASHINGTON and RICHMOND, Calif., ... ) announced today the presentation,of data demonstrating that ... HIV infection by treatment with zinc finger DNA-binding,protein ...
... Growth in Core ... Clinical Business, SUNNYVALE, Calif., Oct. 28 ... of $44.9,million, an increase of 24% over the third quarter of fiscal ... revenue of $36.3,million and a net loss of $4.7 million, or $(0.09) ...
Cached Biology Technology:Japanese Cancer Association and Debiopharm Honour Japanese Research 2Japanese Cancer Association and Debiopharm Honour Japanese Research 3Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 2Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 3Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 4Sangamo BioSciences Presents Data at ICAAC Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 5Cepheid Reports Third Quarter Revenue of $44.9 Million 2Cepheid Reports Third Quarter Revenue of $44.9 Million 3Cepheid Reports Third Quarter Revenue of $44.9 Million 4Cepheid Reports Third Quarter Revenue of $44.9 Million 5Cepheid Reports Third Quarter Revenue of $44.9 Million 6Cepheid Reports Third Quarter Revenue of $44.9 Million 7Cepheid Reports Third Quarter Revenue of $44.9 Million 8Cepheid Reports Third Quarter Revenue of $44.9 Million 9Cepheid Reports Third Quarter Revenue of $44.9 Million 10Cepheid Reports Third Quarter Revenue of $44.9 Million 11Cepheid Reports Third Quarter Revenue of $44.9 Million 12Cepheid Reports Third Quarter Revenue of $44.9 Million 13
(Date:7/24/2014)... drug that successfully treated lupus in mice, a biomedical engineer ... to expand his research to a new version of the ... autoimmune diseases., Chandra Mohan, Hugh Roy and Lillie Cranz Cullen ... study in Arthritis Research & Therapy outlining the use of ... reduced the number of cases of lupus-related kidney disease., He ...
(Date:7/24/2014)... virus living inside your gut that has gone undetected ... researchers at San Diego State University has found that ... a newly described virus, named crAssphage, which infects one ... Bacteroidetes . This phylum of bacteria is thought to ... The research appears today in Nature Communications ., ...
(Date:7/23/2014)... the pitcher, a thirsty bird happens upon a vessel of ... finds the water level out of his reach. Not strong ... into it one at a time until the ... , Highlighting the value of ingenuity, the fable demonstrates that ... It also characterizes crows as pretty resourceful problem solvers. New ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3Newly discovered gut virus lives in half the world's population 2Newly discovered gut virus lives in half the world's population 3Smarter than a first-grader? 2Smarter than a first-grader? 3Smarter than a first-grader? 4
... and China has produced a first draft of the papaya ... of the plants gene coding sequence, sheds new light on ... genetically modified plant, the newly sequenced papaya genome offers the ... the plant resistant to the papaya ringspot virus. The ...
... with good oral health could become the first tool ... to periodontal disease treatments, say researchers at the University ... called HtpG, the bug that makes it is Porphyromonas ... also has potential as a vaccine candidate, according to ...
... the University Hospital of Magdeburg (Germany) have discovered ... and oxidative stress followed by the activation of ... target gene expression in atrial tissue. Their study ... Experimental Biology and Medicine. Multiple tachycardia-associated factors appear ...
Cached Biology News:First draft of transgenic papaya genome yields many fruits 2First draft of transgenic papaya genome yields many fruits 3Presence of certain antibodies signals healthier teeth and gums 2Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia 2
ANTI CORTIS BIN GLOB...
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
ANTI S. ENTERID LPS...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... and serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
Biology Products: